Pharmacists often give nod on meds: survey

Share this article:
Pharmacists often give nod on meds: survey
Pharmacists often give nod on meds: survey

Pharmacists, recent data suggest, may be influencing patients' drug decisions to the tune of nearly seven over-the-counter products and five prescription drugs, on average, per day. Findings imply that these HCPs remain a crucial, and accessible, touchpoint for patients and marketers alike.

Kantar Media's 2013 Pharmacy Readership study surveyed more than 130,000 US pharmacists. Of those, 39% of full-time pharmacists were retail staff and 30% were retail managers; 9% of those polled overall were also members of formulary committees.

On average, they made 4.8 prescription recommendations and seven OTC recommendations per day. Those numbers were slightly elevated from last year's results, which found 4.5 recommendations for prescriptions and 6.7 for OTC.

However, for a group that is filling 265 prescriptions on average per day, the potential to influence up to five prescribing decisions is a drop in the bucket. 

Kantar also found that the conversation starting, "Which do you recommend?" is a common one. Of the pharmacists polled, 52% of their customers requested a drug substitution and, somewhat unsurprisingly, pharmacists are recommending a generic drug 85% of the time over a branded drug (when they have the option to do so).

While pharmacists may be pushing generics over branded, they have signaled a willingness to listen to pharma. Fifty seven percent said their policy toward sales representatives is to see “all or most” of them.

They're also engaging more on smartphones and tablets during the work day. The results showed a 2% jump in smartphone usage (pictured) from year-to-year while at work, and a 7% jump in tablet usage, as well.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...